

INDEVUS PHARMACEUTICALS INC  
Form 8-K  
February 18, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

February 13, 2004

**Indevus Pharmaceuticals, Inc.**

---

(Exact name of registrant as specified in its charter)

Delaware  
(State or other  
jurisdiction of  
incorporation)

000-18728  
(Commission  
File Number)

04-3047911  
(IRS Employer  
Identification  
Number)

**One Ledgesmont Center**

**99 Hayden Avenue**

**Lexington, Ma 02421-7966**

---

(Address of principal executive offices)

**Registrant's telephone number, including area code:**

---

(781-861-8444)

**Item 7. Exhibits**

99.1 Press Release of the Registrant dated February 13, 2004.

**Item 12. Results of Operations and Financial Condition**

The information contained in this report on Form 8-K is being furnished by Indevus Pharmaceuticals, Inc. under Item 12 of Form 8-K. This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On February 13, 2004, the Company issued a press release announcing its first quarter fiscal 2004 results and the timing of a conference call to provide an update on the Company's current product candidates, including the regulatory review process for trospium. A copy of the press release is attached as Exhibit 99.1 to this report.

The exhibit hereto contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under Risk Factors and elsewhere, and include, but are not limited to: dependence on the success of trospium; the early stage of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly trospium; risks associated with contractual agreements; dependence on third parties for manufacturing and marketing; competition; need for additional funds and corporate partners, including for the commercialization of trospium and for the development of pagoclone; failure to acquire and develop additional product candidates; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; limited patent and proprietary rights; dependence on market exclusivity; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; and other risks.

